Page last updated: 2024-09-05

sb 203580 and damnacanthal

sb 203580 has been researched along with damnacanthal in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(damnacanthal)
Trials
(damnacanthal)
Recent Studies (post-2010) (damnacanthal)
3,48941,13755030

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)damnacanthal (IC50)
Tyrosine-protein kinase LckHomo sapiens (human)0.3185
LIM domain kinase 1Homo sapiens (human)0.8
LIM domain kinase 2Homo sapiens (human)1.53

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1

Other Studies

1 other study(ies) available for sb 203580 and damnacanthal

ArticleYear
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007